- Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
[作者:Lee, SM; Woll, PJ; Rudd, R; Ferry, D; O'Brien, M; Middleton, G; Spiro, S; James, L; Ali, K; Jitlal, M; Hackshaw, A,期刊:Journal of the National Cancer Institute, 页码:1049-1057 , 文章类型: Article,,卷期:2009年101-15]
- Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as m...
- Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
[作者:Kurian, AW; McClure, LA; John, EM; Horn-Ross, PL; Ford, JM; Clarke, CA,期刊:Journal of the National Cancer Institute, 页码:1058-1065 , 文章类型: Article,,卷期:2009年101-15]
- Contralateral second primary breast cancers occur in 4% of female breast cancer survivors. Little is known about differences in risk for second primary breast cancers related to the estrogen and progesterone receptor (ho...
- Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis
[作者:Liu, SJ; Zhang, HW; Gu, CY; Yin, JH; He, YC; Xie, JX; Cao, GW,期刊:Journal of the National Cancer Institute, 页码:1066-1082 , 文章类型: Article,,卷期:2009年101-15]
- The association between hepatitis B virus (HBV) mutations and hepatocarcinogenesis remains controversial because of conflicting data in the literature. We conducted a meta-analysis of case-control and cohort studies to e...
|